14.15
+0.13(+0.93%)
Currency In USD
| Previous Close | 14.02 |
| Open | 14.01 |
| Day High | 14.33 |
| Day Low | 13.82 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Volume | 480,321 |
| Average Volume | 991,584 |
| Market Cap | 574.71M |
| PE | -83.24 |
| EPS | -0.17 |
| Moving Average 50 Days | 12.93 |
| Moving Average 200 Days | 31.6 |
| Change | 0.13 |
If you invested $1000 in Keros Therapeutics, Inc. (KROS) since IPO date, it would be worth $704.68 as of June 01, 2025 at a share price of $14.15. Whereas If you bought $1000 worth of Keros Therapeutics, Inc. (KROS) shares 3 years ago, it would be worth $429.44 as of June 01, 2025 at a share price of $14.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewswire Inc.
May 29, 2025 10:55 AM GMT
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nas
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees
GlobeNewswire Inc.
May 27, 2025 5:45 PM GMT
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockhold
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE)